GTX INC /DE/ Form 8-K September 07, 2006

Table of Contents

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

FORM 8-K CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report: **September 7, 2006** (Date of earliest event reported)

GTx, Inc.

(Exact name of registrant as specified in its charter)

Delaware 005-79588 62-1715807

(State or other jurisdiction of incorporation or organization)

(Commission File Number)

(I.R.S. Employer Identification No.)

3 N. Dunlap Street 3rd Floor, Van Vleet Building Memphis, Tennessee 38163 (901) 523-9700

(Address, including zip code, and telephone number, including area code, of registrant s principal executive offices)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

TABLE OF CONTENTS

ITEM 7.01 Regulation FD Disclosure.

ITEM 9.01 Financial Statements and Exhibits.

SIGNATURE

Ex-99.1 Press Release

Table of Contents

ITEM 7.01 Regulation FD Disclosure.

On September 7, 2006, GTx publicly announced today that they have entered into a definitive agreement under which Ipsen will have an exclusive license to develop and market GTx s Acapoder® (toremifene citrate) in all indications except breast cancer, in Europe (European Union, Switzerland, Norway, Iceland, Lichtenstein and the Commonwealth of Independent States) (European Territory), a copy of which is furnished as Exhibit 99.1 to this Current Report. This release is furnished by GTx pursuant to Item 2.02 of Form 8-K and is not to be considered filed under the Exchange Act, and shall not be incorporated by reference into any previous or future filing by the Registrant under the Securities Act or the Exchange Act.

ITEM 9.01 Financial Statements and Exhibits.

(c) Exhibits

Exhibit

Number Description

99.1 Press Release issued by GTx, Inc. dated September 7, 2006

Table of Contents

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

GTx, Inc.

Date: September 7, 2006 By: /s/ Henry P. Doggrell

Name: Henry P. Doggrell

Title: Vice President, General Counsel &

Secretary